Cost-Effectiveness Analysis of Medications in the Field of Sexual Medicine Offered by the Brazilian Universal Healthcare System at a Tertiary Hospital
Abstract
Medicine is an indispensable component of healthcare systems. However, ensuring its availability, accessibility, rational use, cost-effectiveness, and sustainability poses challenges for most countries throughout the world. The present study involved a retrospective analysis of 7,929 medical appointments recorded in electronic medical records from 2016 to 2020 at a general specialty outpatient clinic of a tertiary-level teaching and research hospital in Brazil. A total of 1,377 prescriptions were issued for medications in the field of sexual medicine not available through the universal healthcare system, with a focus on erectile dysfunction (ED), offered to 1,015 patients. The results revealed sustainable ways of treating patients in specialized care with more complex drug therapy, even if such drugs are not on the National List of Essential Medications. This study demonstrated the importance of management with a focus on communication and synergistic interaction among healthcare providers. Medications for ED within the scope of the universal healthcare system, even if not available through pharmaceutical assistance programs, had a low rate of access through the courts (0.8%) compared to other specialties, but were offered in a cost-effective manner.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.